Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
Ended Project Grant Awarded Last action
- Award ID
- R44DK139877
- Recipient
-
Xylyx Bio, Inc. UEI N2N9KL2Y52X1
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,707,755
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Description
- Abstract
- Xylyx is developing engineered human liver fibrotic lesions as a predictive cell-based assay platform to address the lack of in-vitro drug testing assay products containing human fibrotic liver ECM in the market. Liver fibrosis is a progressive disease process underlying multiple chronic liver diseases (nafld, nash, ASH, hepatitis C) and leads to cirrhosis, which causes over 1 million deaths/year worldwide. Nash alone affects 4% of the global population, and 30 million people in USA, where annual mortality exceeds 48,000. No drug is approved to treat liver fibrosis, underscoring the inadequacy of current liver fibrosis models and the necessity of better drug testing assays. The extracellular matrix (ECM) is known to play critical roles in liver fibrogenesis and fibro-proliferation. Animal models are poor predictors of liver fibrosis in humans, and predictive in-vitro models of liver fibrosis are not commercially available, leaving a significant unmet need and market GAP/opportunity for a physiologically-relevant in-vitro platform that enables high-fidelity cell-based phenotypic assays in engineered human liver fibrotic lesions. This sbir fast track will support development and validation studies for commercialization of a liver fibrosis cell-based assay platform containing engineered human liver fibrotic lesions shown to be consistent with patient data. The technological innovation is the product's engineered human liver fibrotic lesions stemming from proprietary methods for isolating and integrating acellular human fibrotic liver ECM that has the pathological properties of human diseased liver tissue. Our approach integrates nash patient-derived stellate cells, kupffer cells, and hepatocytes in standardized human primary fibrotic liver ECM, enabling predictive in-vitro assays on engineered human fibrotic liver lesions - a unique product and major competitive advantage over all existing assays, which lack human liver fibrotic ECM and histopathology. Our goal is to validate and commercialize a standard liver fibrosis cell-based assay platform for predictive in-vitro modeling of human liver fibrosis to reduce dependence on animal models and DE-risk preclinical decision-making. Specific aims: (1) perform multi-omics and histomorphologic profiling of engineered human fibrotic liver lesions; (2) determine histologic, molecular, phenotypic effects of kupffer cells and hepatocytes on engineered human liver fibrotic lesions; (3) evaluate quality and consistency of engineered human liver fibrotic lesions assay platform; (4) test anti-fibrotic drug candidates using engineered human liver fibrotic lesions assay platform. After successful completion of the fast track project, xylyx will commercialize the liver fibrosis assay platform for scientists in pharma companies in need of predictive fibrotic disease models for drug screening, thus reducing the massive costs associated with late-stage attrition due to poor efficacy, and facilitating development of the first effective drug treatment for millions worldwide with fibrotic liver diseases. As the industry leader in ECM-based kits and assays, xylyx will market the product worldwide in the rapidly growing cell-based assay market ($24.6B in 2022, cagr: 12.7%, projected $60.3B by 2030), advancing drug development in the global nash market ($160.7B by 2030). .
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $967,715 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $370,020 | |
| Original award | $370,020 |
Quick answers
Who received award R44DK139877?
R44DK139877 was awarded to Xylyx Bio, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 1, 2024.
How much is award R44DK139877 worth?
$1,707,755 has been obligated on R44DK139877.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award